Binex
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Binex makes conventional pharmaceutical products, including digestive health tablets and eye drops, and also provides contract development and manufacturing services for biologic medicines, meaning it handles production on behalf of other drug companies.
Its pharmaceutical products are supplied to the domestic Korean market, while its biologics contract manufacturing services target both domestic and international clients. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates two distinct business lines: a chemical pharmaceuticals division anchored by a small number of core products, and a biologics contract manufacturing division run out of dedicated facilities.
Summary is AI-generated and may contain errors · figures from DART filings
Binex describes itself as Korea's first biologics contract development and manufacturing organization (CDMO), with its facilities having passed regulatory inspections by health authorities in the United States, Europe, and Japan.
Binex in five facts
What does Binex do?
Binex makes conventional pharmaceutical products, including digestive health tablets and eye drops, and also provides contract development and manufacturing services for biologic medicines, meaning it handles production on behalf of other drug companies.
Where is Binex listed and in which sector?
Binex (Korean name: 바이넥스) trades under KRX code 053030 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Binex?
Its market capitalisation was US$150.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Binex's latest annual revenue and operating profit?
For fiscal year 2025, Binex reported revenue of US$127.2M, an operating loss of US$3.4M and a net loss of US$2.5M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 29.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 16
- [Amended] Half-year report (2026.06)Oct 14
- [Amended] Supply contract signed
Binex updated a previously disclosed supply contract, now worth US$11.7M, about 10.28% of its recent annual revenue, running through Dec 2027.
Supply contract · Sep 30 - Report on large shareholdings (5% rule) (standard)Sep 18
- [Amended] Supply contract signed
Binex updated a previously disclosed supply contract, now worth US$11.2M, about 12.49% of its recent annual revenue, running through Jul 2026.
Supply contract · Jul 28 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Binex reported consolidated results for FY2025: revenue of US$114M (+29.5% year on year), an operating loss of US$3.06M and a net loss of US$2.22M.
Earnings · Mar 4